We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

50 hedge funds and large institutions have $124M invested in Orchestra BioMed in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

33% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 9

9% more funds holding

Funds holding: 46 → 50 (+4)

2.58% more ownership

Funds ownership: 56.84% → 59.42% (+2.6%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less capital invested

Capital invested by funds: $130M → $124M (-$6.6M)

Holders
50
Holders Change
+4
Holders Change %
+8.7%
% of All Funds
0.87%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
12
Reduced
9
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DKCM
Davidson Kempner Capital Management
New York
+$3.11M
2
KPF
K2 Principal Fund
Ontario, Canada
+$2.64M
3
GL
Governors Lane
New York
+$2.59M
4
PMAM
Picton Mahoney Asset Management
Ontario, Canada
+$812K
5
AAA
Affinity Asset Advisors
New York
+$776K

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$5.79M
2
LGM
Logos Global Management
California
-$2.07M
3
SFM
Sphera Funds Management
Israel
-$1.12M
4
SCM
Suvretta Capital Management
New York
-$560K
5
GPCM
Granite Point Capital Management
Massachusetts
-$539K
Name Holding Trade Value Shares
Change 		Change in
Stake
PVI
26
Pura Vida Investments
New York
$1.1M -$16.3K -1,574 -1%
LGM
27
Logos Global Management
California
$1.02M -$2.07M -200,000 -67%
MS
28
Maven Securities
Jersey
$912K – – –
PMAM
29
Picton Mahoney Asset Management
Ontario, Canada
$802K +$812K +78,507 New
Janus Henderson Group
30
Janus Henderson Group
United Kingdom
$758K +$12.9K +1,244 +2%
Millennium Management
31
Millennium Management
New York
$643K +$362K +35,000 +125%
SCM
32
Shaolin Capital Management
Florida
$510K – – –
BCP
33
Berylson Capital Partners
Massachusetts
$473K – – –
TD Asset Management
34
TD Asset Management
Ontario, Canada
$459K – – –
AC
35
Athanor Capital
New York
$384K -$226K -21,884 -37%
D.E. Shaw & Co
36
D.E. Shaw & Co
New York
$304K +$308K +29,801 New
Alyeska Investment Group
37
Alyeska Investment Group
Illinois
$255K – – –
WAM
38
Wolverine Asset Management
Illinois
$174K +$177K +17,087 New
Nomura Holdings
39
Nomura Holdings
Japan
$157K -$98.3K -9,498 -38%
Geode Capital Management
40
Geode Capital Management
Massachusetts
$105K +$107K +10,388 New
6CM
41
683 Capital Management
New York
$102K – – –
ACM
42
Altium Capital Management
New York
$102K – – –
RCM
43
Rivernorth Capital Management
Florida
$102K – – –
WRBC
44
W.R. Berkley Corp
Connecticut
$101K – – –
FIA
45
FNY Investment Advisers
New York
$51K +$20.7K +2,000 +67%
HI
46
Harbour Investments
Wisconsin
$31K +$10.3K +1,000 +50%
UBS Group
47
UBS Group
Switzerland
$12K +$2.58K +249 +28%
Morgan Stanley
48
Morgan Stanley
New York
$7K – – –
TRCT
49
Tower Research Capital (TRC)
New York
$7K +$1.52K +147 +27%
MF
50
Magnetar Financial
Illinois
$348 +$21.1K +2,036 +6%
1
2
3

OBIO Hedge Fund Activity: Q2 2021 in Review

50 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q2 2021, worth a combined $124M — down 5.1% from $130M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new OBIO positions and 3 closed out — a net gain of 4 holders — while 12 added to existing stakes and 9 trimmed.

The largest buyer was Davidson Kempner Capital Management, adding an estimated $3.11M. The largest seller was Cormorant Asset Management, cutting an estimated $5.79M.

  • 50 institutional investors held Orchestra BioMed (OBIO) as of Q2 2021, up from 46 in Q1 2021.
  • Funds reported $124M of Orchestra BioMed stock for Q2 2021, down 5.1% quarter-over-quarter.
  • 7 funds opened new Orchestra BioMed positions in Q2 2021 and 3 closed out, a net change of +4 holders.
  • The largest Orchestra BioMed buyer in Q2 2021 was Davidson Kempner Capital Management, an estimated $3.11M added.
  • The largest Orchestra BioMed seller in Q2 2021 was Cormorant Asset Management, an estimated $5.79M sold.

Based on aggregated 13F filings for Q2 2021.